Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease

Reuters
17 Apr
April 17 (Reuters) - Uniqure NV ::
*UNIQURE ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO AMT-130 FOR THE TREATMENT OF HUNTINGTON’S DISEASE
*UNIQURE NV: ADDITIONAL REGULATORY UPDATE & GUIDANCE ON BIOLOGICS LICENSE APPLICATION SUBMISSION EXPECTED IN Q2 2025

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 17-APR-202511:17:00.057 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10